Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest announcement is out from Foghorn Therapeutics ( (FHTX) ).
Foghorn Therapeutics has made significant advancements in its drug development programs, particularly in chromatin biology and protein degradation. The company is progressing multiple high-value assets into clinical trials, including FHD-909, a selective SMARCA2 inhibitor, and anticipates updates on the ARID1B program in 2025, positioning itself strongly in the oncology therapeutics market.
More about Foghorn Therapeutics
Foghorn Therapeutics operates in the biopharmaceutical industry, focusing on precision therapeutics for chromatin biology. The company develops first-in-class treatments targeting chromatin regulation, which is implicated in numerous tumors, and leverages its Gene Traffic Control Platform® to create innovative therapeutic candidates.
YTD Price Performance: -8.71%
Average Trading Volume: 152,858
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $233M
Learn more about FHTX stock on TipRanks’ Stock Analysis page.
